FBIO - Fortress Biotech

-

$undefined

N/A

(N/A)

Fortress Biotech NasdaqCM:FBIO Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Location: 1111 Kane Concourse, Bay Harbor Islands, FL, 33154, United States | Website: https://www.fortressbiotech.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

50.77M

Cash

91.34M

Avg Qtr Burn

-18.59M

Short % of Float

15.97%

Insider Ownership

21.11%

Institutional Own.

16.32%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
CUTX-101 (Copper Histidinate) Details
Menkes Disease , Blood cancer

Big Mover™

Susp. Mover™

PDUFA

Approval decision

CAEL-101 Details
Amyloid light chain amyloidosis (Mayo Stage IIIa & Mayo Stage IIIb)

Phase 3

Data readout

Triplex Details
Cytomegalovirus (CMV)

Phase 2

Data readout

Triplex Details
Cytomegalovirus (CMV)

Phase 2

Data readout

Triplex Details
Co-infected w/ Cytomegalovirus (CMV) and Human immunodeficiency virus (HIV)

Phase 2

Data readout

Triplex Details
Cytomegalovirus (CMV) control in pediatric patients

Phase 1/2

Data readout

Dotinurad Details
Chronic refractory gout

Phase 1b

Update

Phase 1

Data readout

Phase 1

Data readout

Phase 1

Data readout

CEVA-101 Details
Traumatic brain injury

Failed

Discontinued